Hematology-Oncology
Latest news
269 articles · 20 / page
Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results
This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in
Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting
This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for target
The NSUN2-FOSB Feedforward Loop: Unlocking m5C-Mediated Survival in Acute Myeloid Leukemia
Researchers identify a novel NSUN2-FOSB-BCL2L1 regulatory axis in AML that drives leukemia stem cell self-renewal through m5C RNA methylation. This pathway offers a potential therapeutic target that spares normal hematopoiesis, suggesting a
Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival
This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor
Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia
This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotox
Standardizing Outcomes Research: A Robust Extraction Pipeline for Hematopoietic Stem Cell Transplantation Registry Data
This review evaluates a novel open-source extraction pipeline designed to standardize and automate the processing of complex HSCT registry data, enhancing reproducibility and precision in clinical outcomes research.
Precision Dosing in Chronic Myeloid Leukemia: Navigating the Intersection of TKI Efficacy and Long-term Tolerability
This clinical review examines the management of treatment-emergent adverse events (TEAEs) in patients with chronic myeloid leukemia. It highlights strategies for dose optimization and proactive toxicity management to balance molecular respo
Beyond Complexity: Why Molecular Features Still Dictate the Prognosis of Chronic Lymphocytic Leukemia
Emerging data from UK clinical trials indicate that while high genomic complexity (HGC) correlates with poor outcomes in CLL, it often serves as a surrogate for other established high-risk markers like TP53 status and telomere length.
Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion
A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.
Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
Challenging the Incurability Paradigm: 15-Year Data Suggests a Cure for Advanced Follicular Lymphoma
The 15-year follow-up of the SWOG S0016 trial demonstrates that approximately 42% of patients with advanced follicular lymphoma may be cured with initial CHOP-based chemoimmunotherapy, with relapse rates dropping significantly after 15 year
Lupuslike Manifestations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case-Cohort Analysis of Clonal Inflammation
MDS and CMML can present with lupuslike manifestations that represent a distinct entity of clonal inflammation rather than idiopathic autoimmunity. This study highlights the need for clone-directed therapies over standard lupus treatments.
Molecular Mimicry Unveiled: How Somatic Hypermutation and Adenoviral Protein pVII Drive VITT
Researchers have identified that a specific somatic hypermutation (K31E) in the IGLV3-21*02/03 allele triggers VITT by causing antibodies intended for adenoviral protein pVII to cross-react with Platelet Factor 4 (PF4), explaining the patho
Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
Europe’s Hidden Hyperinflammatory Crisis: HLH Mortality Rates Nearly Double Over a Decade
A retrospective study across 29 European countries reveals that mortality from haemophagocytic lymphohistiocytosis (HLH) increased significantly between 2011 and 2021, with notable bimodal age peaks and geographical disparities suggesting w
Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4
The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse,
Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia
A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati
Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial
The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard
Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma
A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,
Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
Browse by specialty
Open language-specific specialty feeds and department pages.